全文获取类型
收费全文 | 71663篇 |
免费 | 5508篇 |
国内免费 | 2651篇 |
专业分类
耳鼻咽喉 | 380篇 |
儿科学 | 1078篇 |
妇产科学 | 757篇 |
基础医学 | 11417篇 |
口腔科学 | 886篇 |
临床医学 | 3888篇 |
内科学 | 10523篇 |
皮肤病学 | 1422篇 |
神经病学 | 7379篇 |
特种医学 | 1019篇 |
外国民族医学 | 12篇 |
外科学 | 5766篇 |
综合类 | 7343篇 |
现状与发展 | 11篇 |
预防医学 | 2645篇 |
眼科学 | 878篇 |
药学 | 14229篇 |
13篇 | |
中国医学 | 2448篇 |
肿瘤学 | 7728篇 |
出版年
2023年 | 1248篇 |
2022年 | 1748篇 |
2021年 | 2887篇 |
2020年 | 2337篇 |
2019年 | 2625篇 |
2018年 | 2481篇 |
2017年 | 2419篇 |
2016年 | 2144篇 |
2015年 | 2487篇 |
2014年 | 3862篇 |
2013年 | 4706篇 |
2012年 | 3740篇 |
2011年 | 4457篇 |
2010年 | 3696篇 |
2009年 | 3653篇 |
2008年 | 3735篇 |
2007年 | 3432篇 |
2006年 | 3121篇 |
2005年 | 2622篇 |
2004年 | 2491篇 |
2003年 | 2162篇 |
2002年 | 1664篇 |
2001年 | 1264篇 |
2000年 | 1293篇 |
1999年 | 1070篇 |
1998年 | 1112篇 |
1997年 | 998篇 |
1996年 | 820篇 |
1995年 | 765篇 |
1994年 | 674篇 |
1993年 | 636篇 |
1992年 | 568篇 |
1991年 | 500篇 |
1990年 | 439篇 |
1989年 | 412篇 |
1988年 | 338篇 |
1987年 | 299篇 |
1986年 | 286篇 |
1985年 | 591篇 |
1984年 | 665篇 |
1983年 | 434篇 |
1982年 | 498篇 |
1981年 | 444篇 |
1980年 | 386篇 |
1979年 | 343篇 |
1978年 | 291篇 |
1977年 | 205篇 |
1976年 | 193篇 |
1975年 | 148篇 |
1974年 | 109篇 |
排序方式: 共有10000条查询结果,搜索用时 27 毫秒
101.
Activation of intestinal arginine transport by protein kinase c is mediated by mitogen-activated protein kinases 总被引:1,自引:1,他引:0
102.
鸡抗内毒素卵黄抗体IgY的制备 总被引:2,自引:1,他引:1
目的:研究分别应用内毒素(LPS)、类脂A(LipidA)和大肠杆菌突变株15免疫鸡后其蛋黄中抗内毒素抗体IgY的产量、纯度、效价并筛选最佳免疫抗原。方法:分别应用内毒素(LPS)、类脂A(LipidA)和大肠杆菌J5突变株作为抗原免疫25周龄Leghom鸡,水溶法(WD)提取蛋黄中抗体IgY,双紫外光测定抗体含量,SDS-PSGE电泳检测抗体纯度,细胞酶联染色和ELISA检测抗体特异性、效价及筛选最佳免疫抗原。结果:3种抗内毒素IgY含量和效价分别为14.4mg/ml和1:12 800(J5)、10.61mg/ml和1:12 800(LPS)、9.26mg/ml和1:3200(LipidA),抗体纯度均为95%左右。结论:大肠杆菌突变株J5和内毒素(LPS)为最佳免疫抗原,免疫鸡后其蛋黄中抗内毒素抗体IgY的产量和效价最高。 相似文献
103.
J. Kralovanszky N. Prajda S. Kerpel-Fronius T. Bagrij E. Kiss G. J. Peters 《Cancer chemotherapy and pharmacology》1993,32(3):243-248
Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs. It has been demonstrated that delayed high-dose uridine administration after 5-fluorouracil decreases the extent of myelosuppression and causes faster regeneration of the bone marrow. We studied the biochemical consequences of the gastrointestinal toxicity caused by 5-fluorouracil and the potential of high-dose uridine treatment to influence these adverse effects. 5-Fluorouracil caused dose-related decreases in the biochemical parameters (thymidine kinase, sucrase, maltase, alkaline phosphatase) selected as early markers of the impaired metabolic activity of the intestinal mucosa. The nadir of the biochemical changes was reached between 24 h and 72 h after 5-fluorouracil treatment, and complete regeneration of the mucosa took 6–7 days. Delayed high-dose uridine administration failed to mitigate the severity of the gastrointestinal damage that ensued after 5-fluorouracil treatment, but caused significantly earlier regeneration of the mucosa. 相似文献
104.
B. A. Johnson Donald R. Jasinski Gantt P. Galloway Henry Kranzler Robert Weinreib Raymond F. Anton Barbara J. Mason Michael J. Bohn Helen M. Pettinati Richard Rawson Christopher Clyde 《Psychopharmacology》1996,128(2):206-215
Four hundred and twenty-three alcohol dependent subjects were enrolled into a 12-week randomized, double-blind, placebo-controlled
study to determine the safety and efficacy of the 5-HT2 receptor antagonist, ritanserin (2.5 mg/day or 5 mg/day), in reducing alcohol intake and craving. All subjects received 1
week of single-blind placebo prior to randomization into the 11-week double-blind phase. Additionally, all subjects received
weekly individual sessions of manual-guided cognitive-behavioral therapy. Comparing the single-blind period with endpoint,
there was approximately a 23% reduction in drinks/day; 34% fall in the total number of drinking days/week; 22% decrease in
drinks/drinking day; and a 37% diminution in alcohol craving for all treatment groups. All treatment groups experienced a
beneficial clinical outcome as assessed by the Clinical Global Impression Scale. There was, however, no significant difference
between treatment groups on any of these measures of alcohol drinking, craving, or clinical outcome. Subjects were of relatively
high social functioning at baseline, and this did not change significantly during treatment. Treatment groups did not differ
significantly on either medication compliance or reported adverse events. Ritanserin treatment was associated with a dose-related
prolongation of subjects’ QTc interval recording on the electrocardiogram. These results suggest that alcohol dependent subjects
can show marked clinical improvement within a structured alcohol treatment program. These findings do not support an important
role for ritanserin in the treatment of alcohol dependence.
Received: 30 April 1996/Final version: 3 July 1996 相似文献
105.
Juin Fok-Seang Linda C. Smith-Thomas Sally Meiners Elizabeth Muir Jian-Sheng Du Elizabeth Housden Alan R. Johnson Andreas Faissner Herbert M. Geller Roger J. Keynes John H. Rogers James W. Fawcett 《Brain research》1995,689(2):207
The adult mammalian central nervous system (CNS) lacks the capacity to support axonal regeneration. There is increasing evidence to suggest that astrocytes, the major glial population in the CNS, may possess both axon-growth promoting and axon-growth inhibitory properties and the latter may contribute to the poor regenerative capacity of the CNS. In order to examine the molecular differences between axon-growth permissive and axon-growth inhibitory astrocytes, a panel of astrocyte cell lines exhibiting a range of axon-growth promoting properties was generated and analysed. No clear correlation was found between the axon-growth promoting properties of these astrocyte cell lines with: (i) the expression of known neurite-outgrowth promoting molecules such as laminin, fibronectin andN-cadherin; (ii) the expression of known inhibitory molecules such tenascin and chondroitin sulphate proteoglycan; (iii) plasminogen activator and plasminogen activator inhibitor activity; and (iv) growth cone collapsing activity. EM studies on aggregates formed from astrocyte cell lines, however, revealed the presence of an abundance of extracellular matrix material associated with the more inhibitory astrocyte cell lines. When matrix deposited by astrocyte cell lines was assessed for axon-growth promoting activity, matrix from permissive lines was found to be a good substrate, whereas matrix from the inhibitory astrocyte lines was a poor substrate for neuritic growth. Our findings, taken together, suggest that the functional differences between the permissive and the inhibitory astrocyte cell lines reside largely with the ECM. 相似文献
106.
报道新化合物A-失碳-17β-羟基-17α-乙炔基-Δ3(5),9(10)-雌甾二烯-2-酮2的合成。文中探讨了用炔钾粗品对A-失碳-Δ3(5),9(10)-雌甾二烯-2,17-二酮1和A-失碳-6β,19-环氧-Δ3-雄甾-2,17-二酮3的选择性炔化,分别得标题化合物2(44%)及A-失碳-17β-羟基-17α-乙炔基-6β,19-环氧-Δ3雄甾-2-酮4(65%),4经还原性破开环氧、去羟甲基和去醋酰氧基合成了标题化合物2。四步总收率为34%。 相似文献
107.
B. A. Stoll 《Annals of oncology》1997,8(3):223-225
Background: The study reviews the anticancer properties of naturalisoflavones which occur in especially high concentration in soybeans. Itconsiders the suitability of soybean products for clinical trials aiming toreduce the progression of breast cancer.Methods: Evidence is reviewed that plant isoflavones such asgenistein show cytostatic activity against human mammary cancer cell linesin vitro and can also suppress carcinogen-induced mammary cancer inyoung and mature rats.Results: Plant isoflavones are converted in the bowel to compoundswith potential antioestrogenic and antioxidative properties. These compoundsshow cytostatic activity for both oestrogen receptor-positive and negativehuman mammary cancer cell lines, and also inhibit growth and progress of therat mammary cancer model. The high content of soybean products in the diet ofAsian women has been postulated as one reason for their relatively low breastcancer incidence.Conclusion: Preclinical studies suggest that soybean products begiven priority for clinical trials in breast cancer protection. A pilot studycould test soy protein supplements as long-term adjuvant dietary treatmentafter primary surgery for early breast cancer, looking for a decrease in therisk of recurrence or of second primary tumours. 相似文献
108.
腺病毒介导的HSV—tk基因治疗大鼠脑胶质瘤实验研究 总被引:4,自引:0,他引:4
目的:带有HSV-tk基因的重组腺病毒(AdHCMV-tk)结合核苷类似物(NA)治疗大鼠C6脑胶质瘤。方法:用X-gal染色测定AdHCMV-lacZ转染大鼠C6胶质瘤细胞的效率。用AdHCMV-tk/ACV、GCV离体及活体治疗大鼠C6胶质瘤。结果:AdHCMV-lacZ感染C6细胞效率达100%,AdHCMV-tk感染C6细胞,在病毒感染复数为1000时,GCV和ACV半致死剂量分别为3μg/ml和20μg/ml,Ad-HCMV-tk/ACV治疗大鼠C6胶质瘤模型,大鼠生存期超过90天,而对照组分别为17.0±1.6天(生理盐水组)、14.5±1.3天(AdHCMV-lacZ组),P<0.001。结论:重组腺病毒对靶细胞感染效率可达100%,AdHCMV-tk用GCV的杀伤C6胶质瘤细胞比ACV强,而HSV-tk/ACV用腺病毒介导治疗大鼠脑肿瘤疗效显著。 相似文献
109.
Serotonin (5-HT) is a mediator (through 5-HT1P receptors) of slow EPSPs in myenteric ganglia of the small intestine. The effect of 5-HT can be mimicked by elevating cAMP; therefore, we tested the hypothesis that the slow EPSP-like response to 5-HT is cAMP-mediated. Guinea pig gut was enzymatically dissociated; myenteric ganglia remained intact and were collected by filtration. Neurons in the isolated ganglia retained their ability to manifest the slow EPSP-like response to 5-HT. Exposure to 5-HT raised the ganglionic level of cAMP (ED50 0.3 μM). This effect was not antagonized by the 5-HT1P antagonist, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide (100.0 μM), or mimicked by the 5-HT1P agonist, 5-hydroxyindalpine (10.0 μM). Increases in cAMP were also evoked by the 5-HT1 agonist, 5-carboxyamidotryptamine (10.0 μM), the 5-HT2 agonist, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI; 1.0–10.0 μM), and by the 5-HT4 agonists, renzapride (1.0–10.0 μM) and 5-methoxytryptamine (1.0–10.0 μM); however, neither the 5-HT1/5-HT2 antagonists, spiperone, methysergide, and methiothepin, nor the 5-HT4 antagonist, tropisetron (ICS 205–930; 10.0 μM), were able to inhibit the rise in cAMP evoked by these compounds or by 5-HT (0.1–10.0 μM). The 5-HT-evoked elevation of cAMP was antagonized by ketanserin (10.0 μM), which also blocked the effects of 5-methoxytryptamine and DOI, but not those of renzapride. The effective concentration of DOI, however, was higher than that needed for activation of 5-HT2 receptors, and Northern analysis using a cDNA probe encoding the rat 5-HT2 receptor failed to reveal the presence of 5-HT2 mRNA in myenteric ganglia, although it hybridizes with mRNA of the right size in the guinea pig brain. Compounds that failed to change levels of cAMP or to antagonize the action of 5-HT included 8-hydroxy-di-n-propylamino tetralin, R58639, R88226, and sumatriptan. It is concluded that the receptor responsible for the 5-HT-induced rise in cAMP in ganglia isolated from the guinea pig myenteric plexus is not a known subtype of 5-HT receptor. Since the pharmacology of this novel receptor is different from that of the slow EPSP-like response to 5-HT, the receptor probably does not mediate the slow EPSP. © 1993 Wiley-Liss, Inc. 相似文献
110.
The present study examined the influences of dopamine (DA) receptor stimulation on enkephalin (Met5-enkephalin; ME) and tachykinin (substance P; SP) systems of basal ganglia of Sprague-Dawley rats, lesioned as neonates with 6-hydroxydopamine (6-OHDA). It has been proposed that the neonatal 6-OHDA-lesioned rat could serve as a model for the DA deficiency and self-injurious behavior (SIB) observed in the childhood neurological disorder. Lesch-Nyhan syndrome. In agreement with earlier work, the present study found that the neonatal 6-OHDA treatment at 3 days of age, reduced DA and caused an increase in ME and a decrease in SP content in the striatum and substantia nigra, when tested as adults. Administration of the DA precursor, L-dihydroxyphenylalanine (L-DOPA), to lesioned animals, induced SIB; increased DA and DOPAC levels; produced a greater decrease (-64%) in SP levels in the striatum and substantia nigra than was observed with lesion alone (-28%). The L-DOPA-induced decrease in SP levels and the SIB observed in the lesioned animals were blocked by pretreatment with the D1 receptor antagonist, SCH-23390. Moreover, administration of the D1 receptor agonist, SKF-38393, but not the D2 agonist, LY-171555, to lesioned animals mimicked the L-DOPA responses in all respects, except that the agonists did not alter DA or DOPAC levels. None of the DA agonists or antagonists treatments affected lesion-induced increase in ME levels in the striatum. These results indicate for the first time, that SIB precipitated by DA agonists in neonatal dopaminergic denervated animals, is associated with a marked and selective decrease in SP in the striatonigral SP neurons. This process has two components: (a) a retarded development of the SP system due to neonatal dopaminergic denervation: and (b) a depletion of the remaining SP, presumably by enhanced release due to D1 DA receptor-mediated activation of striatonigral SP neurons. 相似文献